Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation [7]

Lancet

Volumn 349, Issue 9055, 1997, Pages 851-852

  Mackness, Michael I ^a   Arrol, Sharon ^b   Mackness, Bharti ^b   Durrington, Paul N ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOENZYME; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN;

HUMAN; LETTER; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL;

EID: 0030973684     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61755-2     Document Type: Article

References (5)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989; 320: 915-24.
2. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-35.
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
4. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14: 334-36.
5. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-35.